MCMargaret A. Cooley

Margaret A. Cooley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Margaret A. Cooley has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • A. J. Ritchie

    School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia

    1 shared publication
  • A. Jansson

    School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia,1 Computational Biology, Department of Life Science, University of Skövde, Skövde, Sweden2

    1 shared publication
  • Adam J Ritchie

    School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia

    1 shared publication
  • Adam J. Ritchie

    School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, New South Wales, Australia 2052

    1 shared publication
  • Andrew O. W. Yam

    School of Biotechnology and Biomolecular Sciences,1 Centre for Marine Biofouling and Bio-Innovation, The University of New South Wales, Sydney, New South Wales, Australia 20522

    1 shared publication
  • Christine Whittall

    School of Biotechnology and Biomolecular Sciences, University of New South Wales Sydney New South Wales Australia

    1 shared publication

Latest Publications

  • The immunomodulatory Pseudomonas aeruginosa signalling molecule N‐(3‐oxododecanoyl)‐l‐homoserine lactone enters mammalian cells in an unregulated fashion

    by Adam J Ritchie, Christine Whittall, James J Lazenby, Siri Ram Chhabra, David I Pritchard, Margaret A Cooley

    The Pseudomonas aeruginosa quorum‐sensing signal molecule N‐3‐oxododecanoyl)‐l‐homoserine lactone (OdDHL) has been reported to affect the function of a wide range of mammalian cell types, including cells of the immune system. In T cells, it has been reported to inhibit the production of most cytokines, and it has been reported to inhibit the function of antigen‐presenting cells. The intracellular target of OdDHL in these cells remains to be identified, although the lipophilic nature of the molecule suggested that the target could be membrane associated. We explored the association of radiolabelled OdDHL with the membrane and cytoplasm of Jurkat T‐cell lines and of primary murine T cells and dendritic cells. We found that not only did 3H‐OdDHL enter the cytoplasm of Jurkat cells without disproportionate association with the cell membrane, it also reached maximum levels in the cytoplasm very quickly, and that the intracellular concentration was proportional to the extracellular concentration. Similar results were obtained when 3H‐OdDHL was incubated with primary murine T cells or cultured dendritic cells. In addition, we show that the cellular distribution of OdDHL does not significantly alter after stimulation of Jurkat cells or primary murine CD4 T cells with immobilized anti‐CD3, with little activity being associated with nuclear fractions. Together, these data strongly suggest that OdDHL enters mammalian cells by passive mechanisms, and that it does not preferentially associate with the membrane or nucleus upon T‐cell receptor ligation.


  • Open Access

    ThePseudomonas aeruginosaQuorum-Sensing MoleculeN-3-(Oxododecanoyl)-l-Homoserine Lactone Inhibits T-Cell Differentiation and Cytokine Production by a Mechanism Involving an Early Step in T-Cell Activation

    by A. J. Ritchie, A. Jansson, J. Stallberg, P. Nilsson, P. Lysaght, M. A. Cooley

    ThePseudomonas aeruginosaquorum-sensing moleculeN-3-(oxododecanoyl)-l-homoserine lactone (OdDHL) has been reported to have immunomodulatory activity in several systems, although the mechanism of that activity remains to be fully characterized. We demonstrate here, using a defined in vitro model of antigen responses by T-cell receptor (TCR)-transgenic mouse splenic CD4 T cells, that the effect of OdDHL on activation and cytokine production is complete within 4 h of antigen or mitogen stimulation and does not depend on the insertion of OdDHL in the cell membrane, despite a previous report that immunosuppression by homoserine lactones required a minimum acyl chain length of 11 carbons (S. R. Chhabra, C. Harty, D. S. W. Hooi, M. Daykin, B. W. Bycroft, P. Williams, and D. Pritchard, J. Med. Chem.46:97-104, 2003). We also demonstrate that while OdDHL can have toxic effects on nonlymphoid leukocytes, it does not induce significant cell death in T cells at the concentrations (≤10 μM) used in these experiments. In addition, we show that primary and secondary antigen-specific cytokine responses are equally susceptible to inhibition by OdDHL and that the compound inhibits the differentiation of both Th1 and Th2 cells. However, the precise balance of cytokine production by CD4 T cells stimulated in the presence of OdDHL varies with both the antigen concentration and its affinity for the transgenic TCR. Thus, conflicting reports of the nature of the immunosuppression by OdDHL may be due in part to the differences in antigen affinity and concentration in different models.


  • Open Access

    Modification of In Vivo and In Vitro T- and B-Cell-Mediated Immune Responses by thePseudomonas aeruginosaQuorum-Sensing MoleculeN-(3-Oxododecanoyl)-l-Homoserine Lactone

    by Adam J. Ritchie, Andrew O. W. Yam, Kara M. Tanabe, Scott A. Rice, Margaret A. Cooley

    N-3-(oxododecanoyl)-l-homoserine lactone (OdDHL), a quorum-sensing molecule ofPseudomonas aeruginosa, plays an important role in the pathogenesis of the organism through its control of virulence factor expression. Several reports have suggested that OdDHL can also directly modulate host immune responses. However, the nature of the modulation is controversial, with different reports suggesting promotion of either humoral (Th2-mediated) or inflammatory (Th1-mediated) responses. This report describes a series of studies which demonstrate for the first time that in vivo administration of OdDHL can modulate the course of an antibody response, with an increase in ovalbumin (OVA)-specific immunogloblulin G1 (IgG1) but not IgG2a in OdDHL-treated OVA-immunized BALB/c mice compared to levels for controls. In vitro stimulation of lymphocytes from both Th1-biased C57Bl/6 and T-cell receptor transgenic mice and Th2-biased BALB/c mice in the presence of OdDHL demonstrated that OdDHL inhibits in vitro cytokine production in response to both mitogen and antigen, with gamma interferon (IFN-γ) tending to be more inhibited than interleukin-4 (IL-4). In vitro mitogen or antigen restimulation of cells from mice treated with OdDHL in vivo shows effects on cytokine production which depend on the underlying immune bias of the mouse strain used, with a relative increase of IFN-γ in Th1-biased C57Bl/6 mice and a relative increase of IL-4 in Th2-biased BALB/c mice. Thus, the mode of action of OdDHL on T-cell cytokine production is likely to be a relatively nonspecific one which accentuates an underlying immune response bias rather than one which specifically targets either Th1 or Th2 responses.